PubMed:25163405 / 305-571 JSONTXT

Annnotations TAB JSON ListView MergeView

    PubMed_Structured_Abstracts

    {"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T2","span":{"begin":0,"end":266},"obj":"OBJECTIVE"}],"text":"To show the superiority of epinastine 0.05% ophthalmic solution (epinastine) to placebo ophthalmic solution (placebo) and noninferiority to olopatadine 0.1% ophthalmic solution (olopatadine) for cedar pollen antigen-induced ocular itching and conjunctival hyperemia."}

    maxiaofeng52_800_3

    {"project":"maxiaofeng52_800_3","denotations":[{"id":"T7","span":{"begin":27,"end":37},"obj":"CI"},{"id":"T9","span":{"begin":65,"end":75},"obj":"CI"},{"id":"T14","span":{"begin":80,"end":87},"obj":"CI"},{"id":"T15","span":{"begin":109,"end":116},"obj":"CI"},{"id":"T19","span":{"begin":140,"end":151},"obj":"CI"},{"id":"T20","span":{"begin":178,"end":189},"obj":"CI"}],"text":"To show the superiority of epinastine 0.05% ophthalmic solution (epinastine) to placebo ophthalmic solution (placebo) and noninferiority to olopatadine 0.1% ophthalmic solution (olopatadine) for cedar pollen antigen-induced ocular itching and conjunctival hyperemia."}

    wangzhuo19_800_3

    {"project":"wangzhuo19_800_3","denotations":[{"id":"T12","span":{"begin":65,"end":75},"obj":"CI"},{"id":"T14","span":{"begin":27,"end":37},"obj":"CI"},{"id":"T7","span":{"begin":80,"end":87},"obj":"CI"},{"id":"T8","span":{"begin":109,"end":116},"obj":"CI"},{"id":"T25","span":{"begin":140,"end":151},"obj":"CI"},{"id":"T26","span":{"begin":178,"end":189},"obj":"CI"}],"text":"To show the superiority of epinastine 0.05% ophthalmic solution (epinastine) to placebo ophthalmic solution (placebo) and noninferiority to olopatadine 0.1% ophthalmic solution (olopatadine) for cedar pollen antigen-induced ocular itching and conjunctival hyperemia."}